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Summary 
Breast cancer is among the five most common cancers in India. The incidence of 
locally advanced breast cancer (LABC) is high because of lack of awareness about 
health among women. At our center patients with LABC are initially treated with 
neoadjuvant concurrent chemoradiation before primary surgery.  
We studied the role of neoadjuvant chemoradiation in patients with LABC in 
improving outcomes. Data of 135 consecutive patients who presented with LABC 
treated in 2007 was analyzed. All these patients received protocol neoadjuvant 
chemotherapy with concurrent radiation to breast and axilla before primary breast 
surgery.  
Overall, in this cohort of patients‟ disease free survival (DFS) was 72.5% and 
overall survival (OS) was 75% at 5 years. Evaluation of all clinical variables and 
their correlation with outcomes was performed. The prognostic factors that correlated 
with improved DFS on univariate analysis were older age (P = 0.036), clinical nodal 
stage 1 (P = 0.008) and pathological complete response in nodes (P = 0.002). 
Similarly, for OS the factors that correlated on univariate analysis were older age (P 
= 0.There was a statistically significant improvement in disease free survival with 
older age (P = 0.009), clinical tumor size (P = 0.025), clinical nodal stage 1 (P = 
0.014) and pathological complete response in axillary nodes after surgery (P = 
<0.001). In multivariate analysis two models with and without clinical and 
pathological nodal stage was evaluated with other factors that were significant in 
univariate analysis. The best independent prognostic factors predicting better DFS 
were clinical nodal stage (P = 0.009) and pathological nodal stage (P = 0.015) and 
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for OS were age (P = 0.022), clinical nodal stage (P = 0.017) and pathological nodal 
stage (P = 0.009).  
We also evaluated the role of angiogenesis in LABC, by evaluating 
microvascular density (MVD) using CD31 as a marker for blood vessels. Forty three 
out of 55 available tissue paraffin blocks were positively expressing CD31. The 
median MVD of 43 tumors was 52. In view of the small number of samples, there 
was no correlation with outcome.  
Management of locally advanced breast cancer with concurrent 
chemoradiation is feasible and the long term outcome at 5 years is comparable and 
may be superior to other approaches. Further evaluation of MVD by different 
vascular markers is required to assess its importance in LABC.   
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Introduction 
India with a population of 1.2 billion (2011 census) is the most populous democratic 
country in the world and will surpass China by 2025 (1).  Though the incidence of 
communicable diseases is still challenging the burden of non-communicable diseases 
like cancer is increasing in India.  
The incidence of breast cancer has increased over the decades around the 
world. It was estimated that there were 1.5 million cases of breast cancers in 1999 a 
82% increase from year 1990 (2). Breast cancer is the most common cause of cancer 
death among women only next to lung cancer (3).  
The greatest increase in incidence has been in Asian women which peaks in 
the forties in contrast to Western women where it peaks in the sixties (4,5). Fifty 
percent of Indian women are premenopausal (5) and has been projected that majority 
of breast cancer burden will be in Asian women.   
 The incidence of breast cancer in India until about 10 years ago was 10 per 
100,000 women which has increased currently to 23 per 100,000 (6). There were 
115,000 patients with breast cancer and 53,000 deaths (3) in 2008. The rate of 
increase in incidence of breast cancer is 0.5 – 2%  per annum and more so in younger 
age groups (<45 years) (7). As the median age of the population of women in India is 
young, the proportion and median age of patients with breast cancer is also less than 
50. For example, the median age of patients with breast cancer in 6 hospital-based 
cancer registries ranged from 44.2 years in Dibrugarh, 46.8 years in Delhi, 47 years 
in Jaipur, to 49.6 years in Bangalore and Chennai. The average age reported from 
other parts of country varies from 50 – 53 years (National Cancer Registry 
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Programme, 2001) with significant population younger than 35 years (11% at TMH, 
Mumbai  (8), and 26% at SGPGIMS, Lucknow (5)). 
The awareness of breast cancer is good in the West and in addition, better 
screening and health care facilities have improved the survival of patients to >80% in 
North America and Europe compared to 60% and 40% in middle-income and low-
income countries respectively (9). There is even variation in presentation with more 
women presenting in early stage in the West compared to those with advanced 
disease in the developing world (10). 
69 percent of the patients presenting to our hospital have locally advanced 
breast cancer (LABC) (11). Understanding the pathogenesis of the disease will allow 
the development of targeted drugs (including anti-angiogenic therapy) other than 
chemotherapy to tackle this huge burden.  
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Review of literature 
Defining locally advanced breast cancer 
Breast cancer can be grouped clinically into early, locally advanced and metastatic. 
The early breast cancers are stage I and II of AJCC staging system (12). Stage III 
breast cancers are considered to be LABC (13). LABC can be further classified into 
operable (IIIA: T3 with N1; N2 with T1-3) and inoperable (IIIB: T4a, T4b, T4c, T4d; 
IIIC: N3 with any T) cancers. Metastatic disease is any breast cancer which has 
spread beyond supraclavicular nodes (13).  
Locally advanced breast cancers remains a peculiar group although the 
disease is locally advanced, many of the patients do not have metastases. The 
survival of consecutive unselected patients with LABC treated with concurrent 
chemoradiation and surgery at Cancer Institute at 15 years is 48% (11).  
Prognostic factors in locally advanced breast cancer 
A variable which helps in the prediction of outcome of disease is called the 
prognostic factor. Prognostic factors help in better risk stratification of patients with 
breast and tailoring their management. A number of prognostic factors have been 
associated with breast cancer; the most important being tumor size, nodal metastasis, 
histologic subtype, grade of the tumor, estrogen receptor status and the HER-2 
expression in the tumor (14,15). Among them the most important prognostic marker 
is the lymph nodal status. As per United States Surveillance, Epidemiology, and End 
Results (SEER) database the 5-year survival rates dropped from 92% to 81% and 
57% for node-negative, 1-3 nodes and >3 node positive group respectively (16). 
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Although nodal metastasis in breast cancer remains the most important factor, there 
are many other attributes in the tumor that determines outcome in a particular patient. 
The concerted application of modern tools of molecular biology which 
include sequencing and expression studies have helped in identifying approaches to 
and prediction of outcomes in breast cancer e.g., Oncotype Dx (17) and Mammaprint 
(18). The role of such prognostic markers has also helped in developing newer 
targeted therapies against breast cancer.  Angiogenesis being necessary for growth 
and metastasis of cancer has been shown to be a prognostic marker in solid tumors 
including breast cancer.  
Chemoradiation in locally advanced breast cancer 
The use of neoadjuvant therapy in LABC was developed to reduce the size of the 
tumor and to bring inoperable tumors in the purview of surgery. This was 
particularly important when breast conserving surgery was the ultimate goal. In 
addition neoadjuvant chemotherapy in LABC helps in assessing the pathological 
response to such treatment thereby improving further adjuvant therapy (19).   
Surgery although the mainstay of treatment for patients with inoperable 
breast cancer, historically chemotherapy or radiation was given as adjunct to bring 
them under the purview of surgery. The administration of neoadjuvant chemotherapy 
improved the operability in LABC and the response rates have dramatically 
improved over the years with achievement of clinical complete responses ranging 
from 10% to 30% and partial responses of 50-60% (20). Increase in clinical response 
rates was associated with improved pathological response rates (of about one fifth to 
one-third) and survival outcomes (21). The largest trial National Surgical Adjuvant 
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Breast and Bowel Project (NSABP) B-18 trial compared neoadjuvant chemotherapy 
versus adjuvant doxorubicin plus cyclophosphamide in 1523 women with median 
breast tumor size of 3.5cms. There was no difference in OS and DFS in both arms 
(HR = 0.99; 95% CI, 0.85 to 1.16; P = .90) and DFS (HR = 0.93; 95% CI, 0.81 to 
1.06; P = .27) but  a trend towards better OS with neoadjuvant therapy in women 
younger than 50 years was observed (OS: HR = 0.81, P = .06; DFS: HR = 0.85, P = 
.09) (22). Pathological complete response (pCR) in neoadjuvant arm was 13% and 
those who achieved pCR had superior disease free survival (DFS) and overall 
survival (OS) compared to those not achieving pCR (DFS: HR = 0.47, P < .0001; 
OS: HR = 0.32, P < .0001). In the patients who received neoadjuvant chemotherapy 
only 5% were LABC (cT3N1). The phase III EORTC 10902 trial which included 
T1c – T4b tumors and nodal stage ranging from N0 – 1 showed a pCR rate of only 
4% with FEC based chemotherapy (19). NSABP B-27 trial with addition of 
docetaxel to AC chemotherapy could increase the pCR to 26% but the meta-analysis 
of trials of neoadjuvant chemotherapy showed a pCR range of 4% - 29% (23). 
Combining radiation with chemotherapy can improve response rates and 
outcomes in LABC in neoadjuvant setting. Preoperative chemotherapy with AC x 6 
cycles followed by radiotherapy (50 Gy plus a 10 Gy boost) could not significantly 
increase the pCR rate (24). Matuschek et al (25) showed a pCR rate of 29.2% with 
neoadjuvant chemoradiation and were able to do breast conservation surgery in 
50.8% of patients with LABC. With twice a week paclitaxel together with radiation 
given concurrently (45 Gy at 1.8 Gy/fraction) in a phase I/II trial, 34% of patients 
with LABC could achieve pCR (26) with better DFS and OS (27).  
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Table 1: Neoadjuvant chemotherapy trials in breast cancer (22,23,28–31) 
Trials Phase 
(n) 
Tumors Chemotherapy Primary 
end points 
pCR rates 
Royal 
Marsden 
III 
(293) 
T0–4, N0-1 4 × 2MT BCT 89 
versus 78% 
(P =.004) 
pCR 7% 
NSABP 
B-18 
III 
(1493) 
T1–3, N0-1 4 × AC 5 y-OS: 80 
versus 81% 
(ns); 
5 y-DFS: 67 
versus 67% 
(ns) 
 pCR 13% 
EORTC 
10902 
III 
(698) 
T1c–T4b 4 × FEC 4 y-OS 82 
versus 84% 
(P = .38) 
pCR 4%; 
downstaging 
to BCT in 
23% 
ABCSG-
7 
III 
(423) 
T1–3, N0-1 
HR− + high 
risk HR+ 
3 × CMF RFS better 
with 
adjuvant 
therapy (HR 
0.7; P = 
.02); 
no 
difference in 
OS (HR 
0.8; P = .21) 
 pCR 6% 
Meta-
analysis 
IV 
(3946) 
9 
randomized 
trials 
Same regimen No 
difference in 
OS (RR 
1.0); 
no 
difference in 
DFS (RR 
0.99) 
 
pCR range 4–
29% 
NOAH III 
(235) 
HER2+ 
LABC  
3xAP + 4xP + 
4Xec  + 3xCMF 
+ H 
Improved 3-
year EFS 
(71%) 
pCR 43% 
Retrospective analysis of patients with breast cancers at our hospital from 
1990 to 1999 showed that among 1117 patients With CMF based regimen when used 
concurrently with radiation the tumor down staging was possible in 45% of 1117 
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patients and nodal down staging by 57.5% at our hospital (11). In India because of 
lack of general health awareness most of the women with breast cancer present in 
advanced stages as reported by our hospital in the above study in which 65% of 
patients were LABC  
History of angiogenesis 
It is clear that except during embryonic development, physiological angiogenesis 
during adult life does not occur. The only exceptions to this rule are the ovary and 
endometrium where physiological angiogenesis occurs. Normally blood vessels are 
quiescent and pathological neo-angiogenesis is prerequisite for growth of tumors. 
Evidence that tumor releases specific factors for formation of new blood vessels was 
shown in 1939 by Ide et al (32). In 1945, Algire and Chalkley (33) could show that 
angiogenic response was more substantial and earlier in tumor than normal tissues 
when implanted in cat‟s skin. They found that tumor growth was linked to a 
developing vascular network. In 1956, Melwin and Algire (34) demonstrated that 
vaso-proliferative response induced by tumor penetrated the tissue in which it was 
implanted. The distance between implant and host‟s tissue with normal vessels if 
beyond 50μm was unable to induce any kind of response. However tumor tissue 
could. In 1968, Greenblatt and Shubik (35) using Millipore chambers implanted in 
hamsters cheek which was not permeable to tumor cells could demonstrate new 
blood vessel formation with growing tumor was possible by probable release of 
diffusible factor that could pass through the pores. These data were  confirmed in 
chick embryo chorioallantoic membrane using millpore filters tumor fragments laid 
on it (36). 
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In 1963, Folkman and Becker demonstrated that tumor cells implanted into 
isolated organs could not grow beyond 1 – 2 mm diameter and also could not get 
vascularized in presence of free hemoglobin solutions lacking platelets (37). These 
tumor cells when reimplanted into host mice became vascularized and grew beyond 
1 – 2 mm3 (38). This was the first evidence showing that neovascularization is 
prerequisite for growth of tumor. Folkman in 1971 was the first to hypothesize that 
tumor growth is dependent on angiogenesis and that “anti-angiogenesis” could be 
therapeutic by preventing formation of new vessel sprout  (39). Folkman also said 
that for tumor cannot sustain growth beyond 1-2 mm
2
 size without formation of new 
capillary blood vessels. Neovascularization is necessary for providing oxygen and 
nutrients to the dividing tumor cells. 
Judah Folkman is now considered as father of angiogenesis research (40) and 
his concepts have now been widely accepted in this field over the years. 
Angiogenesis and cancer 
Angiogenesis is required for the growth and maintenance of the tumor (39). It is a 
process of formation of new blood vessels from pre-existing blood vessels (41). 
Tumor angiogenesis is proliferation of blood vessels to support the increasing 
demand for oxygen and nutrients by the growing tumor tissue. Angiogenesis can be 
either by vasculogenic mimicry (tumor cell differentiation into endothelial-like cells) 
or by angiogenic stimulus by tumor cells (42). Many subtypes of angiogenesis have 
been described. They are described below.  
a) Sprouting angiogenesis is proliferation of endothelial cells and formation of solid 
spurts with extension towards angiogenic stimulus (43,44),  
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Steps involved in sprouting angiogenesis are (45): 
i. Formation of a capillary sprout from the pre-existing mature blood vessel 
after degradation of basement surrounding the parental postcapillary 
venule. The degradation of basement membrane is thought to be by the 
various pro-angiogenic factors released by the tumor cells including 
proteolytic enzymes like matrix metalloproteinases, cathepsins and 
urokinase plasminogen activator. The capillary sprout is from the 
differentiated endothelial cell which moves towards the angiogenic 
stimulus secreted by tumor cells 
ii. The sprouts migrate towards the angiogenic stimulus, followed by their 
division thus lengthening the “stalk” 
iii. Formation of lumen after the basement membrane and perivascular 
supportive tissue including pericytes are formed. 
The capillary sprouts can be divided into three zones: “tip cells” at growing 
end, which are non-dividing and specialized to migrate towards angiogenic 
stimulus and fuse with other tip cells to form capillary network; intermediate 
zone which has dividing endothelial cells which lengthen the stalk; and the basal 
endothelial cell zone, which are differentiated to form the endothelium with 
lumen formation.  
(b) Splitting angiogenesis (Intussusception) is division of the lumen of an pre-
existing vessel by formation of transvascular tissue pillars which extend into lumen 
splitting the vessel and resulting in formation two vessels (42,46). It is an alternative 
and rapid mechanism of new vessel formation with increase in capillary density 
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within minutes (47) without significant increase in endothelial cell number. It mainly 
occurs in developing embryo but also perhaps in tumors (48). The pathogenesis of 
intussusceptive angiogenesis has not been explored largely and can be a probable 
area for research to find newer ways of treatment for cancer. 
(c) Vasculogenesis is formation of vasculature from endothelial stem cells (also 
called angioblasts), which proliferate into de-novo endothelial cells (49). The 
angioblasts are committed to vascular lineage and they differentiate to form 
immature vascular plexus. Vasculogenesis plays a main role in angiogenesis in 
embryo (50). The origin of endothelial cells has long been debated. Their origin from 
a common stem cell called hemangiobast has been hypothesised which also form 
hematopoietic cells but unequivocal evidence is still lacking (51,52). Origin of 
postnatal vasculogenesis and tumor angiogenesis is still controversial.  
(d) Glomeruloid angiogenesis has also been observed in invasive breast cancer where 
the capillary network form highly complex vascular aggregates resembling 
glomerulus of kidney called glomeruloid bodies (53). It has been associated with 
poor outcomes (54). VEGF has been implicated in its formation and has also been 
inferred to represent vascular remodelling rather than sprouting angiogenesis (55,56). 
(e) Vascular mimicry is a neovascularization strategy in which tumor cells replace 
endothelial cells as cell lining the capillaries. They will also acquire the phenotypic 
characteristics of an endothelial cells (57,58). Such kind of vascular mimicry by 
tumor cells have been seen in ocular melanoma and ovarian cancer (59). Few 
instances of breast tumors where vascular mimicry occurs has also been reported 
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(60). It is important to recognize this entity as conventional angiogenic inhibitors 
may not play a role in the treatment. 
In tumors, because of chronic overproduction of pro-angiogenic factors 
causes uncontrolled development of new blood vessels with concomitant increase in 
number of vessels per unit volume (i.e., microvessel density). The flow of blood in 
these vessels is both spatially and temporally heterogeneous and, sometimes 
oscillating in antegrade to retrograde direction.  
Normal vascular endothelium has uniform single layer of endothelial cells 
which have few cytoplasmic projections. Tumor endothelial cells (TECs) are 
described as having irregular shape and size with ruffled margins, long and fragile 
cytoplasmic projections which extend outwards, across vessel lumen. Intercellular 
gaps are created by the tips of these cytoplasmic projections which penetrate lumen 
creating openings or small intercellular gaps in the vessel wall. These gaps increase 
the permeability of the vessels many fold. CD31 uptake on immunohistochemistry is 
spotty which gives “mosaic” appearance of the endothelium (61). This is because of 
either lack of CD31 expression by TEC or total absence of TEC in the vessel wall  
with occasional tumor cells expressing VE-cadherin fill the gaps in vessel wall (62) 
masquerade as endothelium (63), but this remains controversial (58). 
Tumor cells enter the circulation by these vessels for hematogenous 
metastases and have been shown that with the presence of more immature vessels the 
risk of metastases increases (64). Anti-angiogenic factors were shown to inhibit such 
metastases. Angiostatin which inhibits angiogenesis was demonstrated in mouse 
models that if present at higher concentrations will lead to decreased metastasis 
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(65,66). Decreased VEGF levels in tumor have been associated with defective 
angiogenesis and inhibition of metastasis (67). 
Angiogenesis is restricted to wound healing in normal conditions and is found 
to be sustained in certain pathological conditions like rheumatoid arthritis, psoriasis 
and diabetes (68). In experimental models transplanted breast tumor tissues were 
found to be more angiogenic about 30% compared to normal breast tissue of about 
3%  (69–71).  Angiogenesis being rate limiting for tumor growth as described above, 
breast tumor in order to sustain growth undergoes angiogenic switch before any 
morphological changes are identifiable (72).  As many as 2000 oncogenes and tumor 
suppressor genes expression has been found to be altered in this angiogenic switch 
including Ras, myc, raf, c-erbB-2, c-jun and src (73–77).  
The new tumor vessels that formed are poorly organized and leaky with 
intermittent and sometimes reverse flow(78). This leads to tumor hypoxia and 
microenvironmental stresses with increased tumor clones resistant to treatment. In 
presence of low oxygen tension, hypoxia-inducible factor (HIF) is stabilized 
(hydroxylation of HIF inhibition) with translocation to nucleus. With binding to HIF-
1β and other hypoxia response elements to activate several genes involved in 
angiogenesis, glycolysis, erythropoiesis and apoptosis (79). Also HIF-1α is 
overexpressed in tumors and has been associated with advanced disease and poorer 
prognosis (80–82) but its role in breast cancer is not known because of limited data. 
HIF-2α overexpression has been seen in both tumor cells and in tumor-associated 
macrophages (83,84) with positive association with increased tumor vascularity(84). 
Hence HIF has been found to help in tumor vascular remodelling under hypoxic 
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stress (79). Considering the significant role of HIF in tumor angiogenesis and growth 
significant research is being performed in targeting this pathway (85,86).  
The present research into tumor neo-angiogenesis has also been focusing on 
the modifying factors of tumor microenvironment. Tumor microenvironment is 
different in many aspects as described above because of tissue hypoperfusion by 
disorganized immature vessels and consequent low oxygen tension and poor nutrient 
supply, acidic extracellular fluid pH, increased interstitial pressure and increased pro-
angiogenic factors (87,88). As described above this leads to change in expression of 
at least 2000 genes. These will lead to expression of different genes and proteins in 
tumor endothelial cells and targeting against these genes or proteins can help in 
producing selective drugs targeting the tumor. Using newer methods like serial 
analysis of gene expression (SAGE), microarray platforms, proteomic analysis, and 
bioinformatics data mining different new promising tumor endothelial markers have 
been identified like extra domain B of fibronectin, a series of numbered tumor 
endothelial markers (TEMs), annexin A and ROBO4 (89,90). Only a few targets 
against them have even been successful in animal models (91–93) but it has not been 
shown to be significant in humans breast cancer probably because of more complex 
regulation of angiogenesis and lack of widespread expression of these targets as was 
expected (89).  
Prognostic significance of tumor vascularity 
Use of tumor vasculature and its correlation to prognosticate cancer related outcomes 
was tried as early as in 1972 by Brem in the Folkman laboratory who correlated 
histological grade of brain tumors with neovascularization (94). In 1991 Weidner et 
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al (95) was first to describe the enumeration of microvascular density by 
immunohistochemistry (IHC). Using specific vascular IHC markers, tissue sections 
were identified for areas with increased vasculature (hot spots) under low power 
magnification and then individual vessels were counted in at least 5 such “hotspots” 
under high power magnification. Their average was taken as microvascular density 
(MVD). The most commonly used IHC markers for assessment of vascular density 
are CD31, CD34, and von Willebrand factor (96). To minimize the subjective errors 
in counting vessels by MVD method a computer based method was devised called 
Chalkley count in which a 25-point graticule is used for counting hot spots by 
orienting the points over the area of maximum hotspots (Chalkley grid area: 0.196 
mm2) (97). It provided a better but only relative estimate of the vascular density. It is 
more reproducible minimizing the subjective bias.  
Over the years MVD counting protocols described above has been used in 
many studies and has become the standard for evaluation of tumor angiogenesis. 
MVD has been significantly associated with prognosis and outcome in various 
cancers because tumor growth and metastasis are angiogenesis dependent (98–101). 
Its importance is even more in early stage cancers which tend to relapse with failure 
of available prognostic parameters e.g., in hepatocellular carcinoma of  size <5cms, 
MVD was shown to be independent prognostic marker (102). Tumor angiogenesis is 
also considered as prognostic factor in hematological malignancies. Various studies 
have positively correlated adverse prognosis with increase in bone marrow 
angiogenesis (103,104).  
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Though MVD has been shown to be a prognostic factor, a few studies 
(100,105) could not prove its positive prognostic value. Many reasons have quoted 
for these negative results. Lack of standardization and objective method of 
assessment of MVD, counting of microvessel in area of hot spots under low and 
subsequent high power field leading to subjective bias and inter-observer variation, 
lack of standardized tissue sampling sites for the tumor subtypes in retrospective 
studies, in which mostly archived tumor specimens may be used etc. The use of 
different endothelial markers in different studies is may also have contributed to the 
variation in results. 
Use of computerized or automated method for analyzing the MVD can 
increase the accuracy of future studies as was shown by as shown by Acenero et al 
(106) where automated computer based image analysis of MVD was prognostic 
indicator but not manual counting. Also use of more tumor endothelial specific 
antibodies can increase the prognostic significance like integrin αvβ3 (107). VEGF 
overexpression has been found in various studies to be associated with high MVD, 
advanced stage of tumor (108–111) and in few studies was found to be an 
independent prognostic factor along with conventional parameters (108,110,111). 
Overexpression of other angiogenic markers like PD-ECGF (112–114), bFGF 
(115,116), transforming growth factor (TGF)-β (117–119), angiogenin (120,121), 
tissue factor (122), and COX-2 (123,124) have also been found to be associated with 
poor prognosis in various studies. Evaluation of overexpression of such angiogenic 
factors may be an alternate to overcome the disadvantages associated with use of 
tumor MVD  
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Since many of the angiogenic factors are soluble and diffusible peptides, 
measurement of their levels in body fluids can provide an alternative means to assess 
the tumor activity. High serum and urine bFGF has been found to be associated with 
progressive cancers (125). Serum VEGF levels has been more extensively studied 
and appears promising (126–130). It has been used for response assessment to 
perioperative or post neoadjuvant therapy (131–134) and to antiangiogenic therapy 
targeting VEGF (135). The role of soluble VEGF receptor, and ratio between VEGF 
and soluble VEGF receptor have also been studied (136–138). Correlation between 
serum VEGF per platelet to tumor activity has also been studied in hepatocellular 
cancer (139) considering the fact that circulating platelets can also be source of 
VEGF for which the reliability as a marker has been debated (140).  
Studies have also tried to correlate between tumor angiogenesis and response 
to therapy (chemotherapy and radiotherapy). Dirix et al (1997) was the first to show 
the higher levels of angiogenic factors VEGF and bFGF to be associated with 
progressive disease on chemotherapy. Hyodo et al (141) correlated low VEGF levels 
with responsiveness to chemotherapy in metastatic gastric and colorectal with lower 
levels of VEGF which was not observed with CEA and CA-19.9. Similar results 
were observed with patients undergoing chemoradiation for esophageal squamous 
cell carcinoma (142). 
Although the above studies are promising still there are large lacunae in using 
these markers as the studies have not been entirely consistent in predicting and 
prognosticating cancers. Also because of substantial overlap of levels with healthy 
volunteers and wide variation in levels of these angiogenic markers successful 
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translations to clinical use has not been possible (96). But considering the scope of 
targeted therapies against tumor angiogenesis there is an unmet need for newer 
specific markers for tumor angiogenesis. 
Breast cancer and angiogenesis 
Various studies have shown the role of angiogenesis in pathogenesis of development 
of breast cancer and its aggressiveness. As the vascular density increases the risk for 
development of carcinoma breast increases in fibrocystic disease (143). Many 
angiogenic factors have been implicated in the angiogenesis of breast cancer and 
VEGF (144) has been shown to be the key pro-angiogenic factor. Patients with 
C936T polymorphism in VEGF are protected against breast cancer (145).  Increased 
VEGF expression and increased microvascular density have been shown to be 
associated with aggressive ductal in-situ carcinoma and metastases in women with 
breast cancer (95,146). Increased VEGF is associated with poorer survival outcomes 
even irrespective of nodal status (147) and poorer response to treatment (148) 
(chemotherapy or tamoxifen). 
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Aims and objectives 
1. To evaluate prognostic factors in a cohort of patients treated for LABC in year 
2007. 
2. To evaluate the significance of prognostic factors and correlate it with outcome 
in women with breast cancer.  
3. To correlate expression of CD31 with clinical and pathological parameters before 
and after treatment by univariate and multivariate analysis 
4. To correlate expression of CD31 with outcome i.e. disease free survival and 
overall survival. 
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Chapter 2: Materials and methods 
Patients 
From January 2007 to December 2007 consecutive patients with non-metastatic, 
locally advanced carcinoma of the breast (LABC) will be selected for the study (as 
they will be having a minimum period of follow up of 5 years).  
Locally advanced breast cancer included stage III (A, B, and C). Those 
patients who were found to have early breast cancer or metastatic disease were not 
included in the study. 
Patients with LABC have been treated with the institute protocol of neo-
adjuvant treatment (chemoradiation) prior to definitive surgery (modified radical 
mastectomy or breast conservation surgery). The neoadjuvant chemoradiation 
protocol included neoadjuvant chemotherapy of four to six cycles‟ chemotherapy 
concurrent with external beam radiation (EBRT). 
The protocol chemotherapy which was given q3 weekly included either of 
following of: 
 FAC: 5-Fluorouracil 600mg/m2, Adriamycin 60mg/m2, Cyclophosphamide 
600mg/m
2
 
 FEC: 5-Fluorouracil 600mg/m2, Epirubicin 60mg/m2 and Cyclophosphamide 
600mg/m
2
 
 CMF: Cyclophosphamide 600mg/m2, Methotrexate 50mg/m2, 5-Fluorouracil 
600mg/m
2
 
 TE: Paclitaxel 175mg/m2 and Epirubicin 60mg/m2 
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The protocol for concurrent EBRT fields included whole of breast, axilla and 
internal mammary region with the total dose of radiation of 41.5Gy (180cGy in 21 
fractions). EBRT field also included supraclavicular region if patient had clinical N2 
disease or stage IIIA with high risk features like younger age, hormone receptor 
negative and high grade tumors. EBRT was started with 1
st
 cycle of chemotherapy in 
patients who had cT3N1 disease and among patients with cT4bN0-2 who didn‟t have 
gross breast tissue infection or skin ulceration. Patients with skin ulceration or gross 
breast tissue infection received few cycles of chemotherapy and radiation was added 
when satisfactory reduction in tumor size was documented with physicians‟ 
assessment of tolerance to concurrent radiation.  
At the completion of chemoradiation patients underwent mastectomy with 
axillary dissection followed by radiation to internal mammary region with dose of 40 
- 45Gy if not included during neoadjuvant radiation therapy to patients with inner 
quadrant tumors, level III node positivity or >3 node positivity post-surgery.  
 The diagnosis was established in all patients by fine needle aspirate and 
trucut biopsy from the tumor. The tumor tissue from trucut biopsies of these patients 
were collected from tumor bank for the present study purpose. All patients 
subsequently underwent definitive surgery that included mastectomy. Subsequent to 
the mastectomy patients received further chemotherapy to a total of 6 cycles 
followed by if appropriate hormonal therapy i.e., tamoxifen  
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Material 
The above mentioned group of patients with LABC was followed up to 31
st
 
December 2013 so as to get a follow up period of 6 years (1
st
 January 2008 to 31
st
 
December 2013). Data on all patients that included clinical and pathological features 
including expression of hormonal receptors in the tumor were collected. Analysis of 
clinical features of all patients was performed to assess (by univariate and 
multivariate analysis) prognostic factors that correlate with outcome. Outcome 
measures were defined as pathological response to initial treatment, disease free and 
overall survival. 
Overall survival was defined as duration from date of diagnosis to last follow-up or 
death and disease free survival was defined as duration from date of diagnosis to date 
of relapse or death. 
Methodology of immunohistochemistry 
Paraffin blocks from patients with adequate malignant cells (>70%) were selected for 
further analysis. The antibody used in the study was specific for CD31. 
Immunohistochemistry was performed on the sections from the paraffin blocks as 
follows. 
Formalin fixed paraffin embedded tissues were cut into sections of 4 µm 
thickness and fixed onto glass slides by drying. The tissue sections were mounted on 
coated slides and dried at 60°C overnight. The sections were deparaffinised with 
three changes of xylene and then rehydrated in descending alcohol series of 100%, 
90% and 80%. The CD31 antigen was retrieved by Heat Induced Epitope Retrieval 
(HIER) at 95 °C in water bath with citrate buffer (pH 6) for 10 minutes. The tissues 
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were blocked with Hydrogen peroxide (H2O2) as well as blocking solution 
(Biogenex) to avoid nonspecific binding.  The primary antibody used was undiluted 
mouse anti-human monoclonal antibody, CD31 (Biogenex). The sections were 
incubated overnight at 4°C.  The tissues were further incubated with undiluted 
secondary antibody (Biogenex) for CD31, conjugated with Horse radish Peroxidase, 
for 1 hour at room temperature. The chromogen used was diaminobenzidine (DAB). 
The tissue sections were then counter stained with hematoxylin.  The slides were 
dehydrated with xylene and mounted with a mixture of Distyrene, a plasticizer, and 
xylene (DPX). 
Evaluation of CD31 expression 
We could not use the Chalkley method (149) for evaluation of microvascular density 
as the tumor tissue was too small for counting the hot spots. Hence we counted the 
entire vessels positive for CD31 at 20X magnification. The vessels were counted by 
two independent individuals and the average of both the readings was considered.  
Statistical analysis 
The relationship between the prognostic factors considered (age, clinical tumor size, 
clinical nodal stage, grade, hormonal status, type of chemotherapy, pathological 
response and CD31 blood vessel expression) and outcome measures (overall survival 
and disease-free survival) was evaluated by Cox proportional hazards model using 
the statistical software SPSS v.22.  
The pathological complete response is defined as absence of invasive cancer 
in both the breast and nodes after surgery (150). The overall survival was defined as 
duration in months from date of diagnosis to date of last follow-up or death and 
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disease free survival was defined as duration in months from date of diagnosis to 
date of relapse or death. Univariate analyses of all these prognostic factors are also 
presented. To assess the prognostic information by multivariate analysis because of 
dependency of clinical and pathological nodal status we have split them into two 
separate models for analysis which included age and pathological complete 
responses. We have also presented the survival curves using the method of Kaplan 
and Meier (151).  
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Chapter 3: Results 
Patient characteristics (Table 2 & 3):  
A total of 753 women with carcinoma breast visited to Cancer Institute (WIA), 
Adyar during the study period. Among them 237 patients were found to have locally 
advanced breast cancer. In the present study we included 135 evaluable patients who 
received protocol neoadjuvant chemoradiation.  
A total of 102 patients were excluded from study because of various reasons: 12 
patients were excluded because they defaulted after neoadjuvant chemoradiation or 
refused further treatment; 31 patients were excluded because of their tissue diagnosis 
was established by fine needle aspiration or underwent excision biopsy before 
coming to our hospital and hence didn‟t undergo MRM after chemoradiation; 10 
patients were excluded because they defaulted after diagnosis or after start of 
neoadjuvant chemoradiation; 49 patients data was inadequate because of default due 
to various reasons mentioned above.. 
These 135 patients have been included in the study as they all had underwent 
upfront core needle biopsy followed by neoadjuvant chemoradiation and then 
surgery on breast.  
Median age of these patients was 47 (range 22 - 70) (Figure 1). There were 98 
patients with clinical stage IIIA and 37 were with clinical stage IIIB but none of 
these evaluable patients had stage IIIC. The clinical tumor stage ranged from T2 to 
T4b. There were 9 patients with cT2N2 disease; 89 patients were cT3 and 37patients 
were cT4b. Ninety six patients (71%) were with cN1 and 39 (29%) were cN2 
disease. Among the histological subtypes 126 (93%) patients were having infiltrating 
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ductal carcinoma and 3 each had mucinous, medullary and other subtypes (Figure 3). 
Two patients had grade 1 tumors, 60 were grade 2 tumors and 66 were grade 3 
tumors. For 7 patients the information on grade of tumor was not available. For 
statistical analysis these grade 1 & 2 tumors were grouped as low grade and grade 3 
has high grade.  Patients having ER positive tumors were 75 (55.5%) and patients 
with ER negative tumors were 58 (42.2%) (For two patients ER status was not 
available, Figure 2). Similarly there were 65 (50%) patients with PR positive tumors 
and 65 (50%) with PR negative (PR status for 5 patients was not available). 
Evaluation of c-erb2 receptor was not routinely performed on tumors during 2007 
and therefore not available.   
Eighty nine patients (66%) received FAC chemotherapy, 22 (16.2%) FEC-60 and 
3 (2.2%) patients received Paclitaxel + Epirubicin chemotherapy. Twenty one 
patients (15.5%) received CMF chemotherapy (Figure 4). For statistical analysis all 
these patients have been combined in subgroup receiving anthracycline based 
chemotherapy. For 119 (88%) patients concurrent radiation was started with first 
cycle of chemotherapy and rest 16 patients received radiation in subsequent cycles. 
Among the 135 patients 125 (92.5%) patients underwent Auchincloss type of 
modified radical mastectomy, 8 patients underwent Patey‟s mastectomy and one 
patient underwent segmental mastectomy (breast conservation surgery). One patient 
progressed on chemoradiation and hence surgery on breast was not offered and this 
patient subsequently died of disease. Median number of nodes removed during 
modified radical mastectomy was 11 (range 3 – 25). Median number of nodes 
positive among those who didn‟t attain pCR was 2 (range 1 – 11). Forty seven of 134 
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patients after neoadjuvant chemoradiation had pathological complete response on 
examination of their tumor and nodes at surgery. 
Survival analysis: 
The median follow up of the entire cohort of patients was 72 months. In the cohort of 
135 patients, 36 relapsed, of which 31 patients have died. Overall 101 patients were 
alive and 33 were dead at the conclusion of study period. 4 patients who had relapsed 
during the study period are still alive and doing well. At a median follow-up of 72 
months, the median DFS and OS had not yet reached. At 5 years disease free survival 
and overall survival were 72.5% and 75% respectively. The Kaplan-Meier curves for 
disease free survival and overall survival has been shown in Figure 5. 
Univariate analysis (Table 10): 
Age and outcomes:  
There were 94 patients aged <50 and 41 >50 years (median age = 47). The univariate 
analysis (continuous) showed a statistically significant improved outcome with 
increasing age for both DFS (HR: 0.96; 95% confidence interval [CI], 0.93 to 0.99; P 
= 0.036) and OS (HR: 0.95; 95% CI, 0.92 to 0.99; P = 0.009). By univariate 
(Categorical) analysis (Table 10) of age subgroups classified as age <50years and 
patients aged >50years, older age patients fared better than younger age patients for 
overall survival (Log-rank P = 0.011). Older age group showed a trend towards 
better DFS by categorical analysis but was not statistically significant (Log-rank P = 
0.091).  
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Tumor grade and outcomes: 
The grade was divided into two subgroups; high grade (grade 3) and low grade 
(grade 1 & 2).  Age distribution and hormonal status in comparison with tumor grade 
has been shown in Table 4 & 5. Univariate analysis (Table 10) showed that tumor 
grade was not predictive of disease free survival (HR: 1.06; 95% CI, 0.54 to 2.06; P 
= 0.86) or overall survival (HR: 1.33; 95% CI, 0.67 to 2.67; P = 0.41).    
Hormonal status and outcomes: 
The comparison of ER status with age and pathological response has been shown in 
Table 6 & Table 7. Nineteen patients (25.3%) with ER positive group relapsed and 
died because of disease and 17 patients (29.3%) relapsed (HR: 1.24; 95% CI, 0.64 to 
2.39; P = 0.51) and 14 (24.5%) died (HR: 1.03; 95% CI, 0.51 to 2.02; P = 0.97) in 
the ER negative group. 
Similarly PR status was available for 130 out of 135 patients. Of these 65 patients 
were PR positive and 65 were PR negative. In PR positive group 15 patients (23%) 
relapsed and in PR negative group 20 (30%) relapsed (HR: 1.55; 95% CI, 0.80 to 
3.01; P = 0.19). A total of 14 (21.8%) and 19 (29.6%) patients died in each group 
respectively (HR: 1.49; 95% CI, 0.75 to 2.98; P = 0.25).  
Clinical stage and outcomes: 
Stage IIIA and IIIB were the only evaluable patients that were included in the study 
as described in the section of patient characteristics. Overall reduction in size of the 
tumor and nodes was observed following chemotherapy in 129 out of 135 patients. 
Reduction in the size of the tumor was possible in 8 out of 9 (88.8%) patients with 
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cT2 tumors; 87 out of 89 (98%) patients with cT3 tumors; and 34 out of 36 (94%) 
patients with cT4 disease. In cT2 tumors 3 out of 9 patients relapsed and died, in cT3 
tumors 17 out of 89 patients relapsed and died, and in cT4 tumor 14 out of 37 
patients relapsed and died. There were no statistically significant outcome (DFS and 
OS) differences in any of these groups (Table 10).  
Overall, 99 out of 134 patients had complete pathological absence of tumor in 
axillary lymph nodes. Seventy eight out of 96 patients with cN1 were ypN0 and 21 
out of 38 cN2 diseased patients had pathologically sterile nodes post neoadjuvant 
chemoradiation. In cN1 20 out of 96 patients (20%) relapsed and with cN2 disease 
16 (41%) relapsed of 39 patients (HR: 2.43; 95% CI, 1.26 to 4.69; P = 0.008). 
Nineteen of the cN1 relapsed patients died and 15 of cN2 relapsed patients died 
during the study period (HR: 2.3; 95% CI, 1.18 to 4.59; P = 0.014).   
Chemotherapy and outcomes:  
A total of 110 patients received FAC or FEC based chemotherapy, out of whom 39 
of these achieved pCR and the remaining 71 had an incomplete response. Seven 
patients who had achieved pCR relapsed and 22 patients relapsed in the group who 
had not achieved pCR. Twenty one patients received CMF chemotherapy among 
which 7 achieved pCR, 4 died among those who didn‟t achieve pCR but none in 
those who achieved pCR. In our study cohort 3 patients had received 
Paclitaxel/epirubicin chemotherapy. All three of them are alive with one patient not 
achieving pCR after neoadjuvant chemoradiation. On comparison between 
anthracycline and CMF based chemotherapy there was no statistically significant 
difference in outcomes in both groups.  
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Pathological response and outcomes: 
In 135 patients one patient progressed on neoadjuvant chemoradiation hence she was 
not operated upon. In the remaining 134 patients, 54 achieved tumor sterilization in 
breast and 80 didn‟t (Table 8). In the pathological complete tumor response group 13 
relapsed and in incomplete response group 22 relapsed (Log-rank P = 0.713) and 
similarly 12 and 21 died in each group respectively (Log-rank P = 0.899).  
Among the 134 patients who underwent mastectomy 28 patients had pN1, 9 
patients had pN2, 2 patients had pN3 disease, and 95 patients were node negative 
(Table 9). Among the pN1 group 11 patients (29.3%) relapsed, among the pN2 group 
4 (44.4%) relapsed, among the pN3 both patients relapsed and among pN0 18 
patients (18.9%) relapsed during the follow up period. On comparison between 
pathological node negative and positive group there was significant survival benefit 
in both DFS (HR: 2.79; 95% CI, 1.44 to 5.43; P = 0.002) and OS (HR: 3.48; 95% CI, 
1.75 to 6.91; P = <0.001).  
A total of 47 patients achieved complete pathological response among 134 
patients (One patient progressed on chemoradiation hence didn‟t undergo 
mastectomy). Among the 47 patients who achieved pCR 8 patients (17%) relapsed 
and among the 87 patients who didn‟t achieve pCR 27 relapsed (31%) (HR: 1.86; 
95% CI, 0.86 to 4.16; P = 0.113). Only 7 out of 47 patients who attained pCR died 
and 26 in 87 patients who didn‟t achieve pCR (HR: 2.06; 95% CI, 0.89 to 4.76; P = 
0.08).  
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Multivariate analysis (Table 11 & 12): 
In Multivariate analysis the variables which had significant influence on survival 
outcomes in univariate analysis were evaluated. Among the various variables which 
were significant in univariate analysis, the clinical and pathological nodal stages 
were dependent variables hence two different models were used excluding each 
other. The age, clinical tumor size and pathological complete response had bearing 
on the outcomes and hence were taken as independent variables for analysis by Cox 
regression multivariate analysis of outcomes. The pathological nodal stage emerged 
as the strongest variable for predicting overall survival (HR: 3.15; 95% CI, 1.35 to 
7.45; P = 0.009). The clinical nodal stage (HR: 2.33; 95% CI, 1.16 to 4.65; P = 
0.017) and age (HR: 0.28; 95% CI, 0.10 to 0.82; P = 0.02) were also found to have 
significant prediction for overall survival. Surprisingly the clinical nodal stage 
emerged as a better variable than pathological nodal stage for correlation with 
disease free survival (HR: 2.44; 95% CI, 1.24 to 4.79; P = 0.009). The pathological 
nodal stage also a significant predictor of disease free survival (HR: 2.67; 95% CI, 
1.20 to 5.89; P = 0.015). Age was not statistically significant for disease free survival 
unlike overall survival. 
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Table 2: Baseline Characteristics 
Variable N (%) 
Age 
21 – 30 years 5 (3) 
31 – 40 years 30 (22.2) 
41 – 50 years 59 (43.7) 
51 – 60 years 27 (20) 
61 – 70 years 14 (10.3) 
AJCC Stage 
IIIA 98 (72) 
IIIB 37 (28) 
IIIC 0 
T stage 
T2 9 (6.6%) 
T3 89 (66%) 
T4 37 (27%) 
N stage 
N1 96 (71%) 
N2 39 (29%) 
Grade 
1 2 (1.5%) 
2 60 (44.5%) 
3 66 (49%) 
Not evaluable 7 (5%) 
Histological subtypes 
Infiltrating ductal carcinoma 126 (93.3) 
Medullary carcinoma 3 (2.2) 
Mucinous carcinoma 3 (2.2) 
Others 3 (2.2) 
Hormonal status 
ER positive 75 (55.5%) 
ER negative 57 (42.2%) 
Hormonal status not available 3 (2.2%) 
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Table 3: Chemoradiation and other outcome characteristics 
Variable N (%) 
Type of chemotherapy 
FAC 89 (65.9) 
FEC-60 22 (16.2) 
CMF 21 (15.5) 
Paclitaxel + Epirubicin 3 (2.2) 
Number of cycles of neoadjuvant chemotherapy 
3 cycles 8 (5.9) 
4 cycles 18 (13.3) 
5 cycles 5 (3) 
6 cycles 104 (77) 
Number of cycles of neoadjuvant chemotherapy given before radiation was 
started 
After 1
st
 cycle 119 (88.1) 
After 2
nd
 cycle 9 (6.6) 
After 3
rd
 cycle 5 (3) 
After 4
th
 cycle 1 (0.7) 
After 5
th
 cycle 1 (0.7) 
Pathological tumor stage 
0 54 (40) 
1 46 (34) 
2 30 (22.2) 
3 4 (29.6) 
Pathological nodal stage 
0 94 (69.6) 
1 28 (20.7) 
2 9 (6.6) 
3 2 (1.4) 
Pathological response 
pCR 47 (34.4) 
No pCR 87 (64.4) 
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Table 4: Comparison between age and tumor grade 
 Tumor grade Total 
Low High 
Age 
<50 years 44 46 90 
>50 years 18 20 38 
Total 62 66 128 
Table 5: Comparison between ER and tumor grade 
 Grade Total 
Low Grade High Grade 
ER 
Positive 42 30 72 
Negative 20 35 55 
Total 62 65 127 
 
Table 6: Comparison between age and ER status 
 ER Total 
Positive Negative 
Age 
<50 years 49 44 93 
>50 years 26 14 40 
Total 75 58 133 
 
Table 7: Comparison between ER and pCR 
 pCR Total 
pCR No pCR 
ER 
Positive 19 56 75 
Negative 27 30 57 
Total 46 86 132 
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Table 8: Comparison between clinical and pathological tumor stage 
 Pathological tumor stage Total 
0 1 2 3 
Clinical tumor stage 
2 5 3 1 0 9 
3 34 30 23 2 89 
4 15 13 6 2 36 
Total 54 46 30 4 134 
 
Table 9: Comparison between clinical nodal stage and pathological nodal stage 
 Pathological Node Total 
Positive Negative 
Clinical Node Stage 
1 18 78 96 
2 21 17 38 
Total 95 39 134 
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Figure 1: Age distribution 
 
 
Figure 2: Hormone status 
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Chapter 4: Evaluation of tumor angiogenesis by CD31 
Paraffin blocks of 55 patients‟ core needle biopsy could be retrieved form the tumor 
bank out of the 135 patients in the study. Positive staining for CD31 was observed in 
43 samples. The tumor tissue was inadequate for immunohistochemical staining for 
five samples. Seven samples had no expression of CD31 on immunohistochemical 
staining. These 7 samples were restained for CD31 and were still negative. They 
were thus excluded from study.  
The Chalkley method of counting the blood vessels could not be applied 
because the biopsy tissue had inadequate number of hotspots. Thus all the blood 
vessels in tissue sample were counted. The number of blood vessels was counted by 
two independent observers. The average count of the two observers was considered 
for statistical analysis. The median number of blood vessels with CD31 expression 
was 52 and the mean value was 91.  
The median value of 51 was considered for statistical analysis. The blood 
vessel count ranges from 3 to 391. Thus mean value can distort the statistical 
analysis. Hence the median value of 51 was considered for analysis  
The number of patients with blood vessel count lower than the median was 
22. Sixty eight percent of these patients were ER positive and 52% were PR positive. 
Fifteen tumors among them were high grade (grade 3) and 7 were low grade (grade 
2). There were 14 Stage IIIA and 8 stage IIIB patients. Similarly, the number of 
patients with blood vessel count higher than median was 21. Among them 62% and 
50% were ER and PR positive respectively. This category contained 9 high grade 
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and 12 low grade tumors. Fourteen of them were stage IIIA and 7 were stage IIIB 
patients.  
The pathological complete responses were observed in 9 patients in both the 
groups of low and high blood vessel count and 12 didn‟t have complete pathological 
response. One patient progressed on treatment with neoadjuvant chemoradiation and 
hence didn‟t undergo surgery. This patient was having a CD31 blood vessel count of 
30. The univariate analysis (Table 13) for survival outcomes was performed by 
classifying the patients into two groups (≤52 and >52). The high CD31 count didn‟t 
had a statistically significant correlation with either DFS (HR: 0.558; 95% CI, 0.19 
to 2.42; P = 0.56) or OS (HR: 0.386; 95% CI, 0.10 to 1.46; P = 0.16).  
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Table 13: CD31 Count Data 
SL No Index No Stage Pathology Grade ER PR CD31 Count 
1 217 IIIB 1 3 1 2 37 
2 226 IIIB 4 3 1 1 52 
3 227 IIIA 1 2 2 2 290 
4 228 IIIA 1 2 1 1 286 
5 233 IIIA 1 2 1 1 286 
6 235 IIIB 1 3 1 1 107 
7 238 IIIA 1 2 1 1 146 
8 240 IIIA 1 3 2 NA 37 
9 293 IIIA 1 3 1 1 5 
10 296 IIIA 1 3 1 2 347 
11 355 IIIA 1 2 2 2 13 
12 369 IIIA 1 3 2 2 175 
13 415 IIIB 1 3 2 2 136 
14 455 IIIB 1 3 2 2 3 
15 480 IIIA 1 3 2 1 6 
16 493 IIIA 4 3 1 1 8 
17 500 IIIB 1 3 2 2 84 
18 515 IIIA 1 2 1 1 40 
19 528 IIIB 1 3 2 2 30 
20 531 IIIA 1 2 1 2 9 
21 539 IIIA 1 2 1 1 75 
22 545 IIIB 1 2 1 1 48 
23 550 IIIA 1 3 1 1 81 
24 552 IIIA 1 2 1 1 9 
25 558 IIIB 1 2 1 1 233 
26 568 IIIB 1 2 1 NA 55 
27 574 IIIB 1 3 1 1 9 
28 575 IIIA 1 2 1 2 3 
29 576 IIIA 1 3 2 2 24 
30 583 IIIA 1 3 1 1 46 
31 591 IIIA 1 3 1 1 114 
32 615 IIIB 1 2 1 1 7 
33 616 IIIB 1 2 1 2 245 
34 622 IIIA 1 3 1 1 11 
35 629 IIIA 3 NA 1 2 97 
36 639 IIIB 4 3 1 1 18 
37 673 IIIA 1 3 2 2 13 
38 684 IIIA 1 3 2 2 85 
39 686 IIIA 1 2 2 2 391 
40 702 IIIA 1 2 2 2 221 
41 714 IIIA 1 3 1 1 73 
42 715 IIIA 1 3 1 2 26 
43 737 IIIB 1 2 2 1 156 
Stage: AJCC Clinical stage; Pathology: 1- Infiltrating ductal carcinoma; 2- Medullary carcinoma; 3- 
Mucinous carcinoma; 4  - Others); NA: Not available 
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Figure 10: Expression of CD31 in Normal Breast Tissue Hematoxylin and Eosin 
stain and CD31 under magnification 10x (A & B), and 40x (C & D) respectively. 
The CD31 count was faintly expressed. 
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Figure 11: Low expression of CD31 in LABC tumor tissue Hematoxylin and 
Eosin stain and CD31 under magnification 10x (A & B), 40x (C & D). The CD31 
count expression is low in this tumor tissue (arrow). 
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Figure 12: High expression of CD31 in LABC tumor tissue Hematoxylin and 
Eosin stain and CD31 under magnification 10x (A & B), 40x (C & D). The CD31 
expression was high in this tumor tissue (arrow). 
 
.  
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Figure 13: Expression of ER and PR in LABC tumor tissue Hormonal receptor 
expression of ER and PR under various magnifications ER (A: 10x; C: 40x ) and PR 
(B: 10x; D: 40x) 
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Chapter 5: Discussion 
The prevalence of LABC is high (152) among women in Indian subcontinent 
compared to developed countries (153) because of poor socioeconomic factors, 
education and awareness towards general health and in particular for breast cancer. 
Treatment of LABC by neoadjuvant chemotherapy to shrink the tumor and bring it 
within purview of mastectomy is routinely performed globally. However, treatment 
by neoadjuvant concurrent chemoradiation has not been routine and is followed in 
only few centres globally. The various studies across the world have shown an 
overall survival between 50 – 60% at 5 years in patients with locally advanced breast 
cancer (153). In our hospital by using concurrent chemoradiation in neoadjuvant 
setting we could achieve an overall survival of about 75% at 5 years. 
 In our study, young patients had a worse prognosis compared to older which 
was statistically significant. This poor prognosis could not be explained by the grade 
or hormonal status as there were near equal number of patients in each of these 
groups. Our study did not show any difference in survival between patients with 
higher grade or hormonal positivity. This is in contrast to major trials on breast 
cancers that have shown better survival in ER positive subgroup of patients by use of 
adjuvant hormonal therapy (154–156). We did not observe any statistically 
significant difference in outcomes between anthracycline based or CMF based 
chemotherapy when added concurrent to radiotherapy. Probably the concurrent 
radiation nullifies the advantage of anthracycline over CMF based chemotherapy but 
the number of cases are too less to substantiate this and needs to be prospectively 
studied in a randomized trial. 
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Though higher pCR was seen in the ER negative subgroup of patients (ER 
negative: 27; ER positive: 19) this did not translate to improved outcomes. It has 
been already shown that ER negative breast tumors have increased sensitivity to 
chemotherapy and has been attributed in part to higher grade of these tumors 
(157,158) but in our study there were near equal number of patients in both 
subgroups (ER positive: 30; ER negative: 35). Hence we could not explain the reason 
for increased pCR in this subset. If c-erb2 status would have been available the role 
of triple negative breast tumors in achieving pCR would have clarified. In NSABP 
B-27 trial the pCR rate increased to 26% by addition of docetaxel to AC regimen 
(22).  The complete pathological response rate in our study was 35% which was 
superior to the NSABP B-27 trial. On univariate analysis, the role of clinical and 
pathological tumor stage did have little influence in the survival outcomes. But 
achievement of pathological complete response in lymph nodes strongly influenced 
the survival outcomes. Interestingly clinical nodal size also had a statistically 
significant prognostic value in predicting the disease free and overall survival which 
was shown by Cox regression analysis.  
There were potential limitations of this study. These were that it was a 
retrospective analysis of clinical data; menopausal status and expression of c-erbB2 
in the tumors were not available. Overall, with a median follow up of 6 years, the 
numbers of events were less and this had an impact on analysis of prognostic factors 
and relating it to outcomes. 
Our study is unique in considering the use of concurrent radiation along with 
neoadjuvant chemotherapy and we could demonstrate an improved disease free and 
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overall survival. This approach is tailored to the average patient presenting at public 
hospitals. The impressive survival of 75% at five years compares favourably with 
any other approach. If one evaluates Adjuvant online with the one set of clinical 
factors as found in this study the overall survival is 72% at 10 years (median age 47, 
T3, Grade II, ER positive and N1). Alternatively, with another set of clinical factors 
(median age 47, T3, Grade III, ER negative and N2) then the 10 year survival is 
32%. As within this study both groups are present, the overall average as predicted 
by Adjuvant online would be approximately 52%. Thus our outcome in this clinically 
challenging group of patients is not inferior and it remains to be seen whether it will 
be superior. However, this approach is not devoid of side effects. Addition of 
radiation during chemotherapy has been associated with increased morbidity in terms 
of local site skin reaction and prolonged chemotherapy induced myleosuppression. 
However morbidity associated with chemoradiation has to be documented 
prospectively and in a randomized trial comparing it with chemotherapy alone. 
Angiogenesis 
CD31 immunohistochemistry was performed on tumors from 43 patients in 
the 55 trucut biopsy slides procured from the tumor bank. The tumor tissue was 
inadequate for immunohistochemical staining for CD31 in 5 patients and was 
negative in 7 (16%) biopsy tissues (repeated twice). The published literature 
documents that negative results can be as high as 20% (159). Considering, that our 
tissues were over 6 years old the 16% negative rate can partially be explained by 
their deterioration of their quality over the years during storage.  
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The studies investigating angiogenesis in breast cancer have been done using 
various markers like CD31, FVIII, CD34 and CD105. Most of these studies have 
been done on the mastectomy specimen where there is adequate tissue for IHC 
staining. They have assessed the microvascular density with outcomes when patients 
were treated with adjuvant chemotherapy. Guidi et al (160) evaluated  the role of 
MVD by employing expression of FVIII as a marker in node positive breast cancer 
from the breast tissues of participants form the CALBG 8541 study. These patients 
had received adjuvant CAF chemotherapy. The study could not find any significant 
association of MVD with relapse-free or OS outcomes. This study however found 
that prominent plexiform vascular patter was associated with decreased OS (P = 
0.0085) by univariate analysis. Similar results with FVIII antigen and outcomes were 
found with another large study involving 685 patients (161). The largest study on 
CD34 antigen used Chalkley method for counting of blood vessels (162). The study 
showed a positive correlation between high expression of CD34 with higher tumor 
size, grade, and nodal metastases. Gasparini et al (147) studied the role of CD31 in 
271 node-positive and 260 node-negative patients. The statistically significant 
correlation was found between CD31 and outcomes which was not with p53 or 
hormonal receptors used in the study. CD105 being more specific marker for 
endothelial tissue has been found to have better correlation with DFS and OS than 
CD34 (163). 
A meta-analysis on the significance of microvessel density in breast cancer 
was published in 2004 (159). The meta-analysis showed that microvascular density 
had an inverse relationship with survival outcomes with vascularity assessed by 
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CD31 and CD34 expression emerging as strong prognostic indicators. The 
commonly used method to count the blood vessels is the Chalkley method because of 
its simple methodology and reproducibility (159).  
As there was relatively less tumor tissue on the core biopsy specimen in our 
study we had to resort to counting the entire tissue slide rather than „hot spots‟. On 
comparison with grade of tumors, our results showed that low CD31 rather than high 
CD31 count was more likely to be associated with higher grade (68.2% versus 45%) 
compared to other studies. We could also not demonstrate statistically significant 
difference in outcome between high and low MVD as determined by CD31 
expressions. This partly because we have evaluated only a third of tumors and the 
number of events in the whole cohort is small. We are continuing the study and plan 
to complete immunohistochemistry on all the 135 patients‟ core needle biopsy slides. 
The generation of additional data will in all probability establish further the role of 
MVD in LABC. To our best knowledge, this may be the first study on the tumor 
blood vessels density in patients with locally advanced breast cancer in India and 
globally.  
Future directions 
Since the emergence of role of tumor angiogenesis in the pathogenesis of cancer, 
there has been increasing research into newer tumor blood vessel specific markers. 
One such specific marker is CLEC14a which belongs to thrombomodulin family of 
receptors (164). It has been found to be specifically expressed in tumor endothelial 
cells. It helps in formation of filopodia and migration of endothelial cells in neo-
angiogenesis of tumor blood vessel (90). Low shear stress due to poor blood flow in 
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the disorganized tumor vasculature has been proposed to induce expression of 
CLEC14a on tumor vessels and pro-angiogenic phenotypes. CLEC14a has been 
found to be strongly expressed on tumor vasculature compared with vasculature in 
healthy tissue (90). Studies on such tumor endothelial cell specific markers may pave 
way for research into designing targeted therapies to tumor endothelial cells sparing 
the normal vasculature. 
 There are newer drugs being developed targeting angiogenesis in the field of 
oncology. Bevacizumab though was given accelerated approval initially by FDA it 
was withdrawn later as it could not show any benefit of survival. Several multi-
kinase inhibitors have been approved in various malignancies e.g., Sunitinib, 
Pazopinib and Regorafenib. Aflibercept being a fusion protein containing the 
extracellular domains of VEGF R1 & R2 have been found to be beneficial in 
metastatic colorectal cancers. But little advances have been made in the field of 
breast cancer targeting angiogenesis. Discovery of newer specific tumor angiogenic 
markers may pave way for specific targeted therapies in the future.  
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Chapter 6: Conclusions 
1. The use of concurrent radiation to chemotherapy in neoadjuvant setting is 
feasible. It can increase the survival rates and needs to be studied 
prospectively in randomized control trials.  
2. Though a retrospective data, our study did show a strong association between 
pathological nodal stage and outcome in patients with locally advanced breast 
cancers. Also younger age is associated with poorer prognosis. 
3. Our study established that further research is required to assess the 
importance of tumor angiogenesis as a predictive factor for outcomes in 
patients with locally advanced breast cancer. 
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Appendix 
Proforma for data collection 
Index No:  
UHID No:  
OP No:  
Patient name:  
Age:  
Date of admission: 
Clinical stage 
1. Tumor size: 
2. Nodal size: 
3. Metastasis: (Y/N): 
Pathology 
1. Biopsy No 
2. Date of reporting of biopsy: 
3. Pathology 
4. Grade 
5. ER 
6. PR 
7. C-erb B2 
Neoadjuvant chemotherapy 
1. Type of chemotherapy 
2. Date of start of chemotherapy 
3. Number of cycles of chemotherapy before surgery 
Neoadjuvant radiation 
1. Date of start of radiation 
2. Dose 
Mastectomy 
1. Date of surgery: 
2. Type of surgery: 
85 
 
Pathological stage 
1. Pathological tumor size: 
2. Pathological nodes positive: 
3. Pathological nodes removed: 
4. Pathological tumor stage: 
5. Pathological nodal stage: 
Adjuvant treatment 
1. Adjuvant chemotherapy 
a. Date of start of chemotherapy 
b. Type of chemotherapy 
c. Number of cycles of chemotherapy 
d. Date of completion of radiation 
2. Adjuvant radiation 
a. Date of start of radiation 
b. Dose 
c. Area 
d. Date of completion of radiation 
Adjuvant hormonal therapy: 
Relapse 
1. Date of relapse 
2. Site of relapse 
Date of expired: 
Date of last follow-up: 
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Clinical data 
Abbreviations:  
T: Clinical Tumor stage 
N: Clinical Nodal stage 
DOD: Date of diagnosis 
BX: Histopathology of trucut biopsy 
1. Infiltrating ductal carcinoma 
2. Mucinous carcinoma 
3. Medullary carcinoma 
4. Others 
Gr: Grade of tumor 
ER: Estrogen receptor 
PR: Progesterone receptor 
NACT: Neoadjuvant chemotherapy 
Cyc: Number of neoadjuvant chemotherapy cycles 
RT: Radiation therapy 
MRM: Date of modified radical mastectomy 
pT: Pathological tumor size 
pN: Pathological nodal positive number 
ADJ CT: Adjuvant chemotherapy 
cyc: Adjuvant chemotherapy cycles 
AJ RT: Adjuvant radiation  
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